We are a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.
Every Cure & Medable
Medable Inc., the industry-leading technology platform for patient-centered clinical trials, will partner with Every Cure by providing specialized software and services to conduct global, remote clinical trials for drug repurposing candidates.
In 2010, our co-founder, Dr. David Fajgenbaum, was diagnosed with Castleman Disease, and nearly died five times. He discovered a new use for an existing drug that had already been approved for another disease – but had never previously been used for Castleman Disease. Now in remission for over 8 years, Dr. Fajgenbaum is dedicated to scaling this approach to help all patients who may benefit. Our team of physicians, scientists, and others brings decades of experience in drug discovery, data science, and clinical research in pursuit of this ambitious mission.
Repurposed cures sit on the shelf for decades because of three systemic problems. First, no organizations are responsible for unlocking the full potential of every drug. Second, no centralized databases exist for repurposing treatments. And third, companies aren’t incentivized to repurpose drugs, especially generic drugs.
Every Cure’s mission is to identify new uses for existing drugs by identifying and evaluating all potential drug repurposing opportunities and conducting clinical trials of the most promising and high-impact opportunities to evaluate their effectiveness for FDA-approval and/or optimal off-label clinical use.
Every Cure is an ambitious effort that will create an enormous amount of social good and impact. We are seeking partnership opportunities across all sectors on healthcare, biotech, academia, and philanthropy.